Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Lineage Cell Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $1.73 Mil. Lineage Cell Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.85 Mil.
Hence, Lineage Cell Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 2.03.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Lineage Cell Therapeutics Receivables Turnover Related Terms
Lineage Cell Therapeutics Receivables Turnover Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LCTX vs NWBO, ABEO, VRXA: Receivables Turnover Comparison
For the Biotechnology subindustry, Lineage Cell Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lineage Cell Therapeutics (LCTX) has a Receivables Turnover of 2.03 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lineage Cell Therapeutics and its competitors. According to the industry distribution chart, Lineage Cell Therapeutics ranks #51 out of 841 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Lineage Cell Therapeutics' Receivables Turnover too high?
Lineage Cell Therapeutics' current Receivables Turnover is 2.03. The Biotechnology industry median Receivables Turnover is 5.29. Lineage Cell Therapeutics' value of 2.03 is 61.6% below this industry median. Based on the distribution chart, Lineage Cell Therapeutics ranks #51 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Receivables Turnover compare to NWBO and ABEO?
According to the Biotechnology industry distribution chart, Lineage Cell Therapeutics ranks #51 out of 841 companies for Receivables Turnover. This places Lineage Cell Therapeutics in the top 6% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. Lineage Cell Therapeutics' value of 2.03 is 61.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lineage Cell Therapeutics's current Receivables Turnover of 2.03 is 61.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Lineage Cell Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lineage Cell Therapeutics's current Receivables Turnover is 2.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.32, compared to a current price of $1.17 — trading 11.4% below its estimated fair value. The current Receivables Turnover is 2.03 and 61.6% below the Biotechnology industry median of 5.29. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Receivables Turnover is 2.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?
Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued.
The current stock price of $1.17 is trading 11.4% below its estimated GF Value™ of $1.32.
GuruFocus considers Lineage Cell Therapeutics to be Modestly Undervalued.
Key valuation signals for LCTX:
Receivables Turnover: 2.03
GF Value™: $1.32 vs. price of $1.17 (11.4% below fair value)
Industry Position: 61.6% below the Biotechnology median (#51 of 841)
No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score
Get the complete analysis for LCTX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LCTX has been successfully added to your 
